The wide-scale analysis of protein expression provides a powerful strategy for the molecular exploration of complex pathophysiological mechanisms, such as the response to antidepressants. Using a 2D proteomic approach we investigated the Flinders Sensitive Line (FSL), a genetically selected rat model of depression, and the control Flinders Resistant Line (FRL). To evaluate gene-environment interactions, FSL and FRL pups were separated from their mothers for 3 h (maternal separation, MS), as early-life trauma is considered an important antecedent of depression. All groups were treated with either escitalopram (Esc) admixed to food (25 mg/kg.d) or vehicle for 1 month. At the week 3, forced swim tests were performed. Protein extracts from prefrontal/frontal cortex and hippocampus were separated by 2D electrophoresis. Proteins displaying statistically significant differences in expression levels were identified by mass spectrometry. Immobility time values in the forced swim test were higher in FSL rats and reduced by antidepressant treatment. Moreover, the Esc-induced reduction in immobility time was not detected in MS rats. The impact of genetic background in response to Esc was specifically investigated here. Bioinformatics analyses highlighted gene ontology terms showing tighter associations with the modulated proteins. Esc modulated protein belonging to cytoskeleton organization in FSL ; carbohydrate metabolism and intracellular transport in FRL. Proteins differently modulated in the two strains after MS and Esc play a role in cytoskeleton organization, vesicle-mediated transport, apoptosis regulation and macromolecule catabolism. These findings suggest pathways involved in neuronal remodelling as molecular correlates of response to antidepressants in a model of vulnerability.
Introduction
Effective antidepressants available for pharmacological therapy of major depressive disorder (MDD) include several tools, sharing the common mechanism of action of interfering with brain monoamine levels either by blocking neurotransmitter re-uptake into pre-synaptic terminals or by inactivating monoamine degradation (Anderson, 2000 ; Arroll et al. 2005 ; Papakostas et al. 2007) . Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) are safe and reasonably efficacious agents often used as first-line pharmacological intervention (Anderson et al. 2008 ; Gartlehner et al. 2008 ; Montgomery et al. 2007) . SSRIs share the therapeutic efficacy of previously developed tricyclic antidepressants (TCAs), with better safety profile and improved tolerability (Anderson, 2000) . The availability of effective agents notwithstanding, a number of problems with MDD pharmacotherapy remain (Rush et al. 2006) . Up to 50-60 % of patients do not respond to pharmacological treatment (Fava, 2003) .
In addition, even when an improvement can be achieved, some symptoms may not be adequately resolved or remission may not be maintained in the long-term (Ghaemi, 2008) . Moreover, although the tolerability profile of SSRIs is improved in comparison to TCAs, there are still issues of non-compliance to therapy due to side-effects (Gartlehner et al. 2008) . Finally, the slow onset of response represents a problem in patients at high risk for suicide (Montgomery, 2006) . Discovering novel targets for therapeutic intervention is thus essential to address unmet medical needs. To this aim, an exhaustive understanding of the molecular mechanism of action of available antidepressants is required. As previously mentioned, effective antidepressants share the acute action of modulating brain monoamine levels, but the long-term mechanisms mediating therapeutic efficacy are unknown. While the acute increase in monoamine transmission happens within hours from antidepressant dosing, the clinical benefits show up after a few weeks, suggesting that long-term molecular adaptations are needed to establish the modifications in brain pathways and circuits that sustain therapeutic improvement. As a molecular basis of antidepressant action a number of possible mechanisms have been proposed based on experimental data, although none are definitely proven (Castren, 2004 ; Leonard, 2001 ; Malberg & Blendy, 2005 ; Mason & Pariante, 2006 ; Pittenger & Duman, 2008 ; Schloss & Henn, 2004 ; Tsankova et al. 2006 ; Warner-Schmidt & Duman, 2006) .
The aim of this study was to elucidate the molecular changes in protein expression in brain regions relevant for MDD after long-term treatment with escitalopram (Esc), a pro-serotonergic antidepressant. We employed the Flinders Sensitive Line (FSL) rats to model brain circuit dysregulations involved in depressive symptoms. This genetically selected rat model of depression displays good face, predictive and construct validity, since behavioural alterations in response to antidepressant treatments and neurobiological changes related to MDD in humans have been reported (Overstreet et al. 2005 ; Yadid et al. 2000) . As controls, we used the Flinders Resistant Line (FRL) rats, which do not show a depressive-like behaviour. In order to evaluate gene-environment interactions, FSL and FRL pups were maternally separated (MS), as early-life trauma is considered an important antecedent of major depression (Brown & Moran, 1994 ; Hammen, 2005 ; Horesh et al. 2008) . Chronic pharmacological treatment was performed with Esc, a highly selective SSRI (Murdoch & Keam, 2005 ; Sanchez et al. 2003) . Protein changes were investigated by a 2D proteomic approach, since wide-scale analysis of protein expression provides a powerful strategy for the molecular exploration of complex physiological and pathophysiological mechanisms. This study was specifically focused on the effect of the genetic background on the modulation of protein expression after Esc treatment [see also companion paper (Piubelli et al. 2010 ) based on the influence exerted by MS]. Both investigations were performed within GENDEP, an Integrated Project financed by the European Union, combining large-scale clinical pharmacogenomic studies on depressed patients with preclinical investigations on animal disease models, focusing on treatment with antidepressants .
Methods

Experimental design
FSL (n=29) and FRL (n=34) rats were maternally separated from postnatal day (PD) 2 to PD 14 (n=17, n=15, respectively). All experiments were performed on male rats. Control groups were not separated. Both MS and control rats were split into groups receiving Esc or vehicle for 1 month (n=7-9 per group ; Supplementary Fig. S1 , available online). One week before the end of treatment, a forced swim test was administered to all rats. At the end of treatment, rats were euthanized and protein extracts prepared from hippocampus (HC) and prefrontal/frontal cortex (P/FC) for proteomic analysis in both brain regions. Image and statistical analyses were performed by comparing samples belonging to the same electrophoretic run. In this paper, we report the results obtained in the following comparisons, based on the role played by genetic background : (i) FSL+Esc vs. FSL ; (ii) FRL+Esc vs. FRL ; and (iii) FSL+MS+Esc vs. FRL+MS+Esc. Additional comparisons focused on the impact of MS are reported in a companion paper (Piubelli et al. 2010) .
Animals
FSL and FRL rats from colonies maintained in the animal facility at the Karolinska Institutet were used. Rats were housed in standard cages at constant room temperature (22¡1 xC) and relative humidity (45-55 %) under a regular 12-h light/dark schedule (lights on 07:00 hours). Rat chow and tap water were freely available. The Stockholm Ethical Committee forEfforts were made to minimize the number of animals used and reduce their suffering.
MS and pharmacological treatment
MS procedure was performed as previously reported in El Khoury et al. (2006) . Pups assigned to the MS group were separated from the dam as a litter for 180 min, beginning at 09:00 hours, from PD 2 to PD 14. Control rats were left undisturbed until weaning, except for the routine cleaning of the cages twice weekly. Body weights were recorded on PD 2 and PD 14 and all pups were weaned on PD 23. Siblings were then separated by sex and housed in groups of 3-5 rats per cage. Only males were included in the study. At PD 41-46 rats were split into groups receiving Esc admixed to food pellets (0.34 g/kg chow for the first 3 wk, 0.41 g/kg chow during the rest of the experiment) or vehicle for 1 month. The antidepressant dose of approximately 25 mg/kg body weight/d was estimated based on the average food intake (y22 g/d), calculated by dividing the total mean daily consumption of pellets per cage by the number of animals per cage. Moreover, in previous experiments we repeatedly measured Esc plasma concentrations, confirming these doses and found no significant differences between cages and animals (Bjørnebekk et al. 2008 ; El Khoury et al. 2006) .
Forced swim test
The forced swim test was carried out after 3 wk of Esc treatment, during the light phase. On the pre-test day, all animals were placed individually in a Plexiglas cylinder (height 450 mm, diameter 190 mm) filled with water at a temperature of 26 xC. After 15 min, rats were removed from the water, dried, and returned to their home cages. The water was changed after each session. On the next day, rats were placed in the same cylinders for 10 min and video-recorded. A trained observer blind to the treatment conditions scored the behaviour of the animals. According to the criteria of Porsolt et al. (1977) , the rat was judged to be immobile when it floated passively, making only small movements to keep its nose above the surface. Moving limbs to break through the water, climbing or diving were judged as swimming.
Sample preparation by focused irradiation
At the end of the pharmacological treatment, rats were euthanized. As in our previous work, we used focused high-energy microwave irradiation of the brain, a method that results in practically immediate cessation of life and enables subsequent accurate measurements of biologically active compounds, such as metabolic products of arachidonic acid, acetylcholine, monoamines and peptides (Mathé et al. 1990 ; Theodorsson et al. 1990 ). An original microwave system (later modified by us) specially built to euthanize rodents, was from Metabostat (Gerling Moore, USA), with maximal power of 5 kW and irradiation time 1-2 s. Left HC and the whole frontal lobe (referred to as P/FC) were rapidly dissected, frozen in dry ice and stored at x80 xC. The weight of the dissected regions showed a variation (expressed as % CV) of 22 and 17 for HC and P/FC, respectively, ensuring the homogeneity of sampling. Each sample was homogenized at 10 % (w/v) in a solubilizing solution (7 M urea, Sigma-Aldrich, USA ; 2 M thiourea, Fluka, Switzerland ; 40 mM Tris, SigmaAldrich ; 3 mM tributylphosphine, Fluka ; 2 % (w/v) 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate (Chaps), Fluka ; 1 % pharmalytes 3.5-10, GE Healthcare, USA ; Complete protease inhibitor cocktail, Roche, Switzerland). Samples were sonicated three times for 10 s on ice using an ultrasonic processor with probe (Ultrasonic 2000, Dynatech Laboratories Inc., USA) and stored at x80 xC. An aliquot was dialysed against 1 % sodium dodecyl sulphate (SDS, Sigma-Aldrich) in water and used to measure protein concentration by BCA method (Pierce, USA), following the manufacturer's instructions.
2D gel electrophoresis
2D gel electrophoresis was performed according to a previously reported method (Carboni et al. 2006a) , with some modifications. Briefly, isoelectric focusing was performed on 17 cm-immobilized pH gradient strips (3-10 nonlinear pH gradient, Bio-Rad, USA). Strips were rehydrated for 16 h with 0.65 mg protein extract in 400 ml of the solubilizing solution already described, adding 10 mM iodoacetamide as alkylating agent (Herbert et al. 2001) and 0.002 % Bromophenol Blue. Focusing was performed at 20 xC for 75 000 V/h at a maximum of 10 000 V in a Protean IEF Cell (BioRad). After equilibration [6 M urea, 2 % SDS, 375 mM Tris (pH 8.8), 4 mM tributylphosphine for 25 min], proteins were separated on polyacrylamide slab gels (8-18.5 % T gradient, 20r20.5 cm, acrylamide and bisacrylamide from Bio-Rad) in a Protean Plus Dodeca Cell apparatus (Bio-Rad) at 18 xC and 12 mA/gel overnight in 25 mM Tris, 192 mM glycine (Sigma-Aldrich), 0.1 % SDS. Staining was performed with Sypro Ruby fluorescent stain (Bio-Rad) and images were acquired with a CCD camera on a VersaDoc 1000 imaging system (Bio-Rad).
Image analysis was performed with PDQuest software (Bio-Rad). In each gel, spots were detected, background was subtracted, and protein spot quantities were defined with the dedicated functions. The map image with the higher number of spots was selected as reference template and spots in the standard map were then matched across the whole gel set. Spot quantities were normalized in each gel for total quantity in valid spots. Spots displaying statistically significant differences were cut with a spot cutter (BioRad). Proteins were identified by peptide fingerprinting mass spectrometry, using the protein identification service of the Proteomics core Facility at the University of Geneva (http://au.expasy.org/ch2d/service/). MS measurements were performed with a matrix-assisted laser desorption ionization/time-of-flight mass spectrometer (Voyager Super STR, Applied Biosystems, USA) in the reflectron mode. Peptide fingerprinting was conducted using Mascot engine [http://www. matrixscience, Matrix Science Ltd, UK (Perkins et al. 1999) ] and Profound (PROWL, The Rockefeller University, USA ; http://prowl.rockefeller.edu/prowl-cgi/ profound.exe) in parallel, against Swiss-Prot and TrEMBL databases. Aldente tools (http://au.expasy. org/cgi-bin/aldente/form.cgi) were also used when results from the former tools were ambiguous. Identifications were considered successful when probability scores exceeded thresholds provided by tool algorithms. Additional criteria for positive identification were the number of peptides matched to the identified protein and the level of sequence coverage.
Statistical analysis
Behavioural data were analysed with three-way ANOVA (factoring for strain, MS, treatment and interactions). A cut-off value of p<0.05 was established. If ANOVA tests revealed significant group differences, post-hoc Fisher's Protected LSD tests were performed. Analyses were performedusing Statistica 8.0 software (StatSoft, Inc., USA).
Proteomics data were log-transformed to meet requirements for a normal distribution and analysed with Student's t test and partial least squares (PLS) analysis with the statistics tools included in the PDQuest software. Spots giving significant results (p<0.05) were verified visually to exclude artefacts. When spots were missing in some gels, quantity values of significant spots were re-checked by Student's t test using Microsoft Excel. (Dennis et al. 2003) were used to obtain Gene Ontology (GO) term enrichment analysis to associate the most relevant GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms with the lists of modulated proteins.
Bioinformatic analysis
DAVID Bioinformatics Resources 2008
Differentially expressed proteins were also evaluated by Ingenuity Pathway analysis (IPA, version 6, Ingenuity Systems, USA ; https://analysis.ingenuity. com/pa). The IPA tool provides computational algorithms to identify protein interaction clusters on the basis of an ' Ingenuity Pathways Knowledge Base ', consisting of relationships between proteins collated from annotation of the biological literature.
Results
Forced swim test
FSL and FRL rats were exposed to MS and received chronic antidepressant treatment (see Experimental design section ; Supplementary Fig. S1 ). After 3 wk of pharmacological treatment, rats were tested in the forced swim test and immobility time values were compared among the different experimental treatments. ANOVA revealed that immobility time varied with strain (p<0.0001), with pharmacological treatment (p=0.02), and with MS (p=0.004). Interactions between strain and treatment (p=0.042) and MS and treatment (p=0.027) were also observed. As expected, post-hoc analyses showed that, in groups receiving no treatments or manipulations, immobility time values were higher in FSL rats than in FRL rats (p=0.012 in LSD test). Antidepressant treatment significantly reduced immobility time only in the FSL strain, although a trend in the same direction was also observed in FRL rats ( Fig. 1a ; FSL+Esc vs. FSL, p=0.007 ; FRL+Esc vs. FRL, p=0.076 in the LSD test). Moreover, Esc treatment did not reduce immobility time in rats that were exposed to MS (Fig. 1 b spots detected in each comparison is reported in Table 1 .
In this study, the following groups were compared in both HC and P/FC samples : (i) FSL+Esc vs. FSL ; (ii) FRL+Esc vs. FRL ; and (iii) FSL+MS+Esc vs. FRL+MS+Esc.
Differential proteomics
After image analysis, volumes (optical density values integrated on spot areas) of matched spots were compared between maps belonging to different groups. Statistical analyses showed that Esc treatment significantly modulated spot levels in the different experimental conditions and in the different strains, as reported in Table 1 . Examples of modulated spots are shown in Supplementary Figs S3 and S4. In the first set of results, the molecular effect of Esc treatment was evaluated in the depressive-like strain FSL and in the control strain ; in both regions and strains, antidepressant treatment induced a comparable number of changes. In the second set of comparisons, the effect of MS and Esc treatment on FSL or FRL backgrounds was compared ; in this comparison, a high number of spot changes was observed in HC.
Spots showing statistically significant changes amounting to at least a 20 % difference between groups were cut from gels and identified by peptide fingerprinting, obtaining an overall success rate of protein identification of 80.5 %. Identities of modulated proteins in the selected comparisons in HC and P/FC are reported in Tables 2-4 . Protein names and accession numbers in the Uniprot database are shown, as well as the quantitative amount of regulation. In addition, GO annotation and KEGG pathway terms are also reported in the Tables to highlight the biological pathways mainly affected by the modulation. 
Bioinformatic analysis
Bioinformatic analyses were performed with the aim of further characterizing cellular pathways affected by the alteration of protein levels in the different experimental conditions. The functional annotation tool in DAVID Bioinformatics Resources was used to highlight the GO terms significantly associated with the modulated proteins in each comparison. The most representative protein categories modulated by Esc treatment in FSL rats were involved in cytoskeleton organization ( Fig. 2 a) ; in FRL rats, carbohydrate metabolism and intracellular transport (Fig. 2 b) . In FSL rats (Table 2) , b-and c-actin, neurofilament light polypeptide, calreticulin, stathmin and F-actin-capping protein are highlighted in HC ; tropomyosin and dihydropyrimidinase-related protein-1 in P/FC. In FRL rats (Table 3 ), 14-3-3 e and b-tubulin isoforms were detected.
A high number of proteins were differently modulated in the two strains by Esc treatment after MS. In HC, affected proteins play a role mainly in macromolecule catabolism and in the regulation of apoptosis (Fig. 2 c, Table 4 ; PDIA3, apolipoprotein E, Rho GDP dissociation inhibitor, peroxiredoxin, prohibitin, PITSLRE serine/threonine-protein kinase CDC2L1), in cytoskeleton organization (actin related protein 2, b-and c-actin, cofilin 1, a-internexin, profilin-2, GFAP) and in vesicle-mediated transport (synapsin-2, NSF, SNAP-a and b, protein DJ-1).
Ingenuity pathway analyses were also performed to evaluate which protein networks were influenced in the different experimental conditions. The integration of proteomic information with the biological correlations based on literature data, found by the IPA system, produced a number of protein networks that could help in interpreting the biological meaning of changes. Figures 3-6 show the most relevant networks, ranked by percentage of experimentally detected proteins vs. total number of proteins in the network.
Discussion
The aim of this work was to analyse the impact of treatment with a pro-serotonergic antidepressant on protein expression in brain regions presumed to be relevant for psychopathological changes in MDD. To achieve this objective, an animal model incorporating gene-environment interactions was used, as both sources of variations are increasingly recognized as important in precipitating the disease and possibly in the response to therapy (Keers et al. 2010 ; Uher, 2008) . Both the FSL strain, showing a depressive-like behaviour and relevant neurobiological impairments (Overstreet et al. 2005 ; Yadid et al. 2000) , and the respective control strain, FRL, were chronically treated with Esc, and both were exposed to an ethologically relevant stress in the early postnatal days. The responses in terms of protein expression revealed that antidepressant treatment indeed exerted a different impact depending on the genetic background, as well as on the consequences of the exposure to stress in the different genetic backgrounds. In this gene-environment interaction model, behavioural tests and proteomic analysis of protein expression were performed. In this paper, all behavioural findings are reported, whereas the focus of molecular analyses was, in particular, placed on the role played by genetic background. The influence of the environmental challenge posed by MS is analysed in a companion paper (Piubelli et al. 2010) . As a caveat, it should be borne in mind that all experiments were performed on males, therefore the general validity of our findings is uncertain. Further experiments should be undertaken in the future to verify whether the observed alterations in behaviour and in protein levels also hold true for females, especially considering the larger incidence of MDD in women.
Behavioural data
A complex interaction between genetic background and response to stress was revealed in the behavioural tests. The immobility time in the forced swim test, a measure of helplessness related to the depressive-like state, was increased in FSL compared to FRL rats, as previously observed (Overstreet et al. 2005) . Immobility time was reduced by chronic treatment with Esc and the effect was more apparent in the FSL strain, as expected from previous experiments (El Khoury et al. 2006) . These findings confirmed the efficacy of the pharmacological treatment. In addition, data analysis showed that, although the exposure to MS early in life per se did not modify immobility time values in the adult, it exerted an impact in the response to antidepressant treatment, thus engendering a sort of animal model of treatment resistance. Although the difference is subtle, this piece of data suggests that responses to antidepressant treatment could be sensitive to complex gene-environment interactions in this model. It is conceivable that the different behaviours could be related to the molecular changes in protein levels observed in the brain regions examined. Similar findings were also obtained in the same experimental paradigm after treatment with the pro-noradrenergic antidepressant nortriptyline (Piubelli et al. unpublished data) .
Esc effects in the different genetic backgrounds
In the first dataset, changes in protein expression levels in HC and P/FC associated with Esc treatment were analysed in both strains. Proteins involved in cytoskeleton organization were altered both in FSL and FRL rats, while changes in neuronal differentiation proteins were specifically detected in FSL animals. Significantly, in FSL rats, modulation by Esc was detected for stathmin, a phosphoprotein located in the cytosol that regulates microtubule turnover, thus reorganizing the microtubule cytoskeleton (Cassimeris, 2002) . Recently, a role for stathmin has been discovered in innate fear circuits and in the control of the formation of fear-related memories in the amygdala (Shumyatsky et al. 2005) . In addition, stathmin is also involved in the pathophysiological mechanisms of schizophrenia and bipolar disorder in relation to its function during neurodevelopment in the PACAP circuitry (Katayama et al. 2009) . It is thus possible that changes in stathmin levels or post-translational modifications could exert a role in the therapeutic efficacy of Esc through an influence on PACAP signalling. In the present study, an effect of Esc on actin isoforms was repeatedly detected ; regulation of actin was associated more often with pharmacological treatment of the FSL strain than with the control FRL rats. The association between a modulation of actin and antidepressant treatment, which has been observed previously (Carboni et al. 2006 b ; Hutchinson et al. 2008 ; McHugh et al. 2008) , can conceivably be related to its function in the regulation of synaptic plasticity, exerted through the alteration of dendritic spine morphology (Schubert & Dotti, 2007) . Indeed, studies performed on animal models and post-mortem brains of mood-disorder patients (Nakatani et al. 2007) suggested the hypothesis that a perturbation of the actin-associated molecular pathway could constitute an underlying mechanism of mood disorders. Consistent with the hypothesis, that study also revealed that F-actin-capping protein, a regulator of actin polymerization, was modulated by Esc. A trend for modulation of F-actin-capping protein mRNA in bipolar-patient brains has been discovered, although neither classical TCAs nor SSRIs were able to influence the expression of this gene in a mouse animal model of depressive symptoms (Nakatani et al. 2007) . Our results support the hypothesis of a dysregulation of the actin cytoskeletal proteins in antidepressant action. Within the hypothesis of the modulation of cytoskeletal proteins, another repeated finding was that Esc also modulated neurofilament proteins. A modulation of the level of neurofilament proteins has been observed in the dorsolateral prefrontal cortex of bipolar depression, MDD and schizophrenia patients (English et al. 2009 ; Law & Harrison, 2003 ; Miguel-Hidalgo et al. 2005) , confirming a role for the disruption of cytoskeleton in the pathophysiology of psychiatric disorders. In addition, in the rat learned helplessness model of depression, a decrease of the L-neurofilament in the HC correlated with depressive-like behaviour, since animals exposed to inescapable stress but not developing the behavioural deficit did not show the decrease of L-neurofilament (Reines et al. 2004) . In this model, treatment with valproic acid both reversed the depressive-like behaviour and L-neurofilament dysregulation (Ferrero et al. 2007) . A modulation of L-neurofilament protein in the brain has been associated with antidepressant treatment (Guest et al. 2004 ; Vaidya et al. 2000) , as well as with a model of a condition associated with MDD, high corticosteroid levels (Cereseto et al. 2006) . Moreover, the stress hyper-responsive Wistar-Kyoto rat strain, whose passive phenotype models some aspects of depression, showed decreased mRNA levels of the three neurofilament subunits in the dorsal raphe nucleus (Pearson et al. 2006) . Within the impact on cytoskeletal proteins, this study also revealed that a modulation of tubulins was induced by Esc treatment in both regions and strains. Previous data have already highlighted the importance of the regulation of tubulin function and post-translational modifications, which control microtubule dynamics, in depression models and antidepressant response (Bianchi et al. 2005 (Bianchi et al. , 2009 Kamada et al. 1999 ; Yang et al. 2009 ). In addition, regulation at the level of gene expression was also observed after antidepressant treatment (Palotas et al. 2004 ; Wong et al. 2004) . Cumulatively, this study provides further support for the importance of the regulation of microtubule dynamics for antidepressant activity.
Calreticulin is a molecular chaperone of the endoplasmic reticulum involved in the regulation of intracellular Ca 2+ homeostasis. We found down-regulation of a calreticulin isoform after Esc treatment in FSL HC. Increased levels of calreticulin were reported in the temporal cortex of depressed patients who died by suicide, suggesting that endoplasmic reticulum stress proteins may be important in the pathophysiology of mood disorders (Bown et al. 2000) . Further supporting the involvement of endoplasmic reticulum stress proteins in mood disorders is the finding that chronic administration of valproate or lithium modulates calreticulin levels (Chen et al. 2000 ; Shao et al. 2006) .
Glutamate dehydrogenase levels were modulated in HC by Esc treatment in both strains, although in opposite directions. An alteration in different posttranslationally modified forms of this enzyme was also detected in the comparison between FSL and FRL lines after stress exposure and pharmacological treatment (Table 4) . Glutamate dehydrogenase is a mitochondrial enzyme that catalyses the conversion of glutamate to 2-oxoglutarate, also exerting a role in glutamatergic neurotransmission (Bao et al. 2009 ; Yudkoff et al. 1991) . Dampening glutamatergic neurotransmission is believed to exert antidepressant The identities of modulated proteins are shown (column 3), with Uniprot accession numbers (column 2) and the standard spot number assigned by the image analysis software (column 1). When more than one spot was identified as the same protein, the respective parameters for each spot are indicated in the same raw and arranged according to the standard spot number of the spot. Experimental/ theoretical values of molecular mass in Da (Mr) and isoelectric point (pI) are reported in columns 4 and 5, respectively. Proteins were identified by Mascot search and also checked by Profound search. Mascot scores are shown in column 6 ; when a protein was identified only by Profound, the Profound expectation value (indicated by *) was reported. Number of identified peptides and sequence coverage are shown in columns 7 and 8, respectively. In column 9, results from statistical evaluations are reported as Student's t test/Partial Least Squares analysis. If the spot was significant in Student's t tests, the p value is indicated or n.a. (not applicable) is reported when the spot was missing in one of the two gel groups. Spot significance by Partial Least Squares analysis (>95 %) is indicated by a +. The size and direction of variation are indicated in the fold changes (FC) column 10. Changes with a large ratio (>100) have been arbitrarily assigned as >100 or f100, depending on the direction of the variation. In columns 11 and 12, Gene Ontology annotation (at biological process level 5 : GOTERM_BP_5) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway terms (when available) were associated to each protein using DAVID tools, in order to categorize them according to their function and the related cellular or disease pathways. When GO annotations were not available, molecular function from Uniprot was reported (in italics). (Skolnick et al. 2009) ; it is therefore conceivable that the regulation of this enzyme (both levels and/or post-translational modifications) may affect the therapeutic efficacy of Esc. Esc treatment in FRL rats also influenced proteins involved in carbohydrate metabolism, such as aldolases and alpha enolase ; overlapping results were also reported by Marais et al. (2009) 
The integrative pathway analysis (Figs 3 and 4 ) confirmed the impact of the antidepressant treatment on the above-mentioned pathways implicated in cellular assembly and organization. These protein networks involve actin and tubulin, with direct and indirect interactions with other proteins which mediate microtubule and neurofilament development and regulation, such as stahmin and L-neurofilament for FSL rats (Fig. 3) ; internexin and DRP2 for FRL rats (Fig. 4) . The networks also revealed correlations with other proteins involved in energy metabolism, such as glycolytic enzymes, or in signal transduction, such as kinases and receptors, underlining the concerted change at cellular level driven by antidepressant treatment.
Comparison between genetic backgrounds in gene-environment interactions
Within the GENDEP project, a thorough examination of the impact of strain and MS exposure on brain mRNA and protein levels has been performed (Blaveri et al. 2010 ; Piubelli et al. unpublished data) . In this work, a comparison was also made between the two genetic backgrounds after exposure to MS and antidepressant treatment. A large number of proteins were differentially modulated, showing that the response to antidepressants is deeply affected by the pre-existing substrate. Changes impinged mainly on pathways involved in cellular macromolecule catabolism, in apoptosis and establishment of cellular localization (Fig. 2 c) .
Several interesting networks were identified by pathway analysis. Among them, the network shown in Fig. 5 primarily involves proteins implicated in cytoskeleton organization and assembly, focusing mainly on actins and actin-binding proteins. In the same network, the actin system is connected with the heat-shock protein (HSP) net and the peroxiredoxins by 14-3-3 zeta. The 14-3-3 proteins play a key role in cell division, differentiation and apotosis, in addition to their function in signal transduction (Berg et al. 2003) ; moreover, they modulate neuronal plasticity events through interactions with cytoskeletal elements (Sun et al. 2003) . Peroxiredoxin 2 and 6 (Fig. 5) are involved in the response to reactive oxygen species and in the cellular redox balance. The difference observed in the two strains could be related to a distinct ability to cope with oxidative stress, which is associated with MDD (Ng et al. 2008) , while an antioxidant effect is exerted by antidepressants, including citalopram (Cumurcu et al. 2009 ; Khanzode et al. 2003) .
The modulation of HSPs is also marked in a second interesting network (Fig. 6) , where they interact with protein disulphide isomerase, protein DJ-1 (represented as PARK7 in the network) and stressinduced-phosphoprotein 1. Protein disulphide isomerase is involved in the regulation of cellular redox homeostasis and is reported to be affected by antidepressant treatment (Carboni et al. 2006b ; McHugh et al. 2008) . A role in oxidative stress is also exerted by Protein DJ-1, a protein involved in dopamine synthesis and contributing to some forms of Parkinson's disease (Ishikawa et al. 2009) . A regulation of this protein has also been observed in the ventral HC of rats subjected to MS (Marais et al. 2009 ). The modulation of proteins involved in apoptosis, protein folding, and in oxidative stress response indicates a differential activation of the cellular repairing and maintenance mechanisms between the two genetic backgrounds in response to MS and antidepressant treatment.
In addition, a differential modulation in the stress hypothalamic-pituitary axis response can be postulated in association with the observed increased levels of pro-opiomelanocortin in FRL rats after MS and pharmacological treatment, in agreement with several pieces of evidence that support a complex interaction among genetic predisposition and stress exposure in the onset of MDD (El et al. 2009 ).
In the same pathway (Fig. 6) , the network connecting some proteins of the SNARE complex (a-SNAP, b-SNAP and N-ethylmaleimide-sensitive factor NSF) is also evident, thus indicating an involvement of the presynaptic exocytotic machinery in the genetic predisposition to depressive-like behaviour. Based on the findings obtained in this pathway analysis, we propose the hypothesis that neuronal adaptation, cellular plasticity and synaptic dysfunction are essential elements of the genetic predisposition to depression in this model.
A large proportion of the observed changes occurred in proteins belonging to the metabolism of cellular carbohydrates and in the amino-acid and nucleotide metabolic processes. Although the high representation of metabolic enzymes could be ascribed to an inherent bias of the 2D gel proteomic approach towards 4, 5.6, 5.7, 5.6, 5.9, 5.9, 6.1/5.3 46, 88, 117, 89, 81, 88, 54 7, 21, 20, 20, 17, 17, 8 22, 49, 45, 43, 47, 45, 26 (Parker et al. 2009) , it is tempting to speculate a relationship with the alteration in brain metabolism observed in mood disorders (Moretti et al. 2003) . As an example, the numerous changes in ATP synthases detected in this study could be linked to the observed reduction in ATP levels in the brain of patients with affective disorders (Moretti et al. 2003) . Similarly, in their proteomic investigation of postmortem brains from psychiatric patients, Beasley et al. whose expression levels were altered in MDD, some of them in common with our study, supporting the view of an altered glucose and nucleotide metabolism as a central component of mood disorders. As already pointed out (Beasley et al. 2006) , these associations should be cautiously viewed, since brain mitochondrial dysfunctions are not unique to psychiatric disorders, but have been found also after central nervous system trauma and in several neurological conditions, suggesting that they may be a generic marker of compromised neuronal function. Nonetheless, the above findings could drive the identification of peripheral biomarkers which reflect brain mitochondrial dysfunctions in psychiatric or neurological patients, providing information on the extent of neuronal function impairment and potentially serving as a putative surrogate marker for disease severity.
Conclusions
In this work, a detailed analysis of molecular changes in brain protein levels induced by treatment with a pro-serotonergic antidepressant was performed in a gene-environment interaction model of MDD in rats. When examining the impact due to the genetic The identity of proteins is indicated by the gene name. ACTB, Actin, beta ; ACTG1, actin, gamma 1 ; ARHGDIA, Rho GDP dissociation inhibitor alpha ; Arp2/3, actin-related protein complex 2/3 ; ARPC2, actin-related protein 2/3 complex, subunit 2 ; CAP1, Cap adenylate cyclase associated protein 1 ; CFL1, cofilin 1 ; COTL1, coactosin-like 1 ; CRK, v-crk sarcoma virus CT10 oncogene homolog ; EHD3, EH-domain containing 3 ; F Actin, Filamentous actin ; HDL, high-density lipoprotein ; HSP, heat-shock protein ; HSP90AA1, heatshock protein 90 kDa alpha ; LASP1, LIM and SH3 domain protein 1 ; Mek, mitogen-associated extracellular signal-regulated kinase ; NFkB, nuclear factor NF-kappa-B ; PEBP1, phosphatidylethanolamine binding protein 1 ; PFN2, profilin 2 ; PGK1, phosphoglycerate kinase 1 ; Pkc(s), protein kinase c ; PKM2, pyruvate kinase 3 ; PLA2, phospholipase A2 ; PPIA, peptidylprolyl isomerase A ; PRDX2, peroxiredoxin 2 ; PRDX6, peroxiredoxin 6 ; Ras homolog, Rho-like Gtpase ; Sos, son of sevenless ; SYN2, synapsin II ; TCR, T cell receptor ; YWHAZ, 14-3-3 zeta/delta. (f 2000-2010 Ingenuity Systems Inc., all rights reserved.)
background, proteins involved in cytoskeleton organization and vesicle-mediated transport were mainly affected. The findings suggest pathways involved in neuronal remodelling as molecular correlates of response to antidepressants in a model of vulnerability to depressive-like behaviour.
Note
Supplementary material accompanies this paper on the Journal's website (http://journals.cambridge.org/ pnp). The identity of proteins is indicated by the gene name. Akt, RAC-alpha serine/threonine-protein kinase ; ALDOA, aldolase 1a ; Ap1, transcription factor AP-1 ; APOE, apolipoprotein E ; BLVRA, biliverdin reductase A ; CRYM, crystallin, mu ; GAPDH, glyceraldehyde-3-phosphate dehydrogenase ; GSTA1, glutathione S-transferase alpha 1 ; Hsp70, heat-shock protein 70 kDa ; Hsp90, heat-shock protein 90 kDa ; HSP90AB1, heat-shock protein 90 kDa alpha, class B member 1 ; HSPA8, heat-shock 70 kDa protein 8 ; IL1, Interleukin 1 ; LDL, low-density lipoprotein ; LMNA, lamin A/C ; MAPK1, mitogen-activated protein kinase 1 ; NAPA, N-ethylmaleimide-sensitive factor attachment protein, alpha (SNAP-a) ; NAPB, N-ethylmaleimide-sensitive factor attachment protein, beta (SNAP-b) ; NME2, nucleoside diphosphate kinase B ; NSF, N-ethylmaleimide-sensitive factor ; PARK7, protein DJ-1 ; PDGF BB, platelet-derived growth factor subunit B dimer ; PDIA3, protein disulfide isomerase family A, member 3 ; PGAM1, phosphoglycerate mutase 1 ; PI3 K, phosphatidylinositol-4-phosphate 3-kinase ; Pka, cAMP-dependent protein kinase ; PLC, lipophosphodiesterase C ; POMC, pro-opiomelanocortin ; PSMA2, 20S proteasome alpha 2 subunit ; Snare, N-ethylmaleimide-sensitive fusion protein attachment protein receptor ; STIP1P, stress-induced phosphoprotein 1. 
